Aicardi syndrome
Rare genetic syndrome with brain, eye, and seizure abnormalities.
Aicardi syndrome is a rare genetic condition that affects brain development, vision, and causes epilepsy. It is named after the French doctor Jean Dennis Aicardi, who first described it in nine girls in 1965. The syndrome involves the partial or complete absence of the corpus callosum, a key structure that connects the brain's two hemispheres. Other features include retinal lacunae (white spots on the retina) and epileptic seizures, typically infantile spasms. Intellectual disability is common, usually moderate to severe. So far, the syndrome has only been found in girls and in boys with Klinefelter syndrome (two X chromosomes).
People with Aicardi syndrome need ongoing specialist care and habilitation. Epilepsy is treated with medication, but additional treatments may be necessary. An early eye exam is important to assess vision and determine if visual aids are needed. Gastrointestinal problems are frequent. In adulthood, continued support and habilitation are required for daily living.
Symptoms usually appear before a baby reaches about five months of age. Development is normal in the first months, but then signs of the syndrome emerge. A small head (microcephaly) is common. Between three and six months, the child starts having epileptic seizures, often flexor spasms where the neck bends forward and the arms clasp. Seizures occur in series and may increase in number until controlled with medication. Epilepsy usually persists for life.
Most individuals have severe intellectual disability, affecting language, communication, and motor skills. A few have moderate disability, and mild disability is very rare. Vision is always affected, and most people have impaired sight. Retinal lacunae appear as white spots in the fundus due to missing pigment cells. If these spots are in the macula, they affect sharp vision. Other eye problems are common, such as microphthalmia (one eye smaller than normal), optic nerve changes, coloboma (incomplete closure of eye membranes), and nystagmus (rapid, involuntary eye movements). Measuring vision accurately is difficult because of intellectual disability.
Gastrointestinal issues are common, including constipation, diarrhea, and gastroesophageal reflux. Some people have trouble eating. Puberty may be early or delayed. Drooling and bruxism (teeth grinding) are common.
Quick Facts
- Field
- Medical genetics, Neurology
Facts from the source article.
Lore & Background
Aicardi syndrome was first described in 1965 by French child neurologist Jean Dennis Aicardi, who reported the condition in nine girls. The original publication appeared in the French journal 'Journal des Sciences Médicales de Lille'. The syndrome is characterized by a triad of features: partial or complete absence of the corpus callosum, retinal lacunae, and infantile spasms. Symptoms typically appear before a baby reaches about 5 months of age, with epileptic seizures often beginning at three to six months. The syndrome is thought to be caused by a mutation on the short arm of the X chromosome (Xp22), but the specific gene or genes involved remain unknown as of 2015.
Reader's Guide
Aicardi syndrome is significant as a rare X-linked dominant disorder that almost exclusively affects females and males with Klinefelter syndrome, due to the likely lethality of the mutation in male fetuses with a single X chromosome. The syndrome's hallmark features—agenesis of the corpus callosum, retinal lacunae, and infantile spasms—form a diagnostic triad, though missing one does not preclude diagnosis. Management focuses on seizure control, early intervention for developmental delays, and addressing comorbidities such as gastrointestinal problems, porencephalic cysts, and hydrocephalus. The condition is non-progressive, but complications lead to increased mortality; the oldest known individuals are in their 40s. No person with Aicardi syndrome is known to have transmitted the gene to the next generation, and all cases are thought to arise from new mutations.
The Clinical Spectrum: From Neonatal Crisis to Stable Adulthood
What was once believed to be an invariably fatal childhood condition has revealed itself as a far more heterogeneous disorder than its earliest descriptions suggested. The original 1984 account portrayed a trajectory of relentless neurological deterioration ending in death during early childhood, yet subsequent case identification has overturned that assumption. Today, clinicians recognize a wide continuum: some patients remain stable well into their forties, while rare individuals carry pathogenic mutations yet experience nothing beyond seasonal chilblain lesions and attend mainstream schools. Siblings within the same household can display dramatically different severities. Roughly one in ten cases manifests in the neonatal period, marked by microcephaly, seizures, feeding failure, jitteriness, cerebral calcifications, white matter damage, and atrophy — a picture so closely resembling transplacental viral infection that the two are easily confused. Hepatosplenomegaly and low platelet counts compound the resemblance. Approximately one-third of these earliest-onset cases, most often linked to TREX1 mutations, do not survive past early childhood. The more common presentation arrives in early infancy, sometimes after months of apparently normal development, when irritability, persistent crying, unexplained fevers, dystonia, and an exaggerated startle response gradually emerge.
Genetic Architecture and Inheritance Patterns
AGS is not the product of a single defective gene but rather a genetically heterogeneous condition traceable to mutations across at least seven distinct loci. These include TREX1, the three subunits of the ribonuclease H2 complex (RNASEH2A, RNASEH2B, RNASEH2C), SAMHD1, ADAR1, and IFIH1 (encoding the MDA5 receptor). A separate gene, OCLN on chromosome 5q13.2, has also been identified in affected individuals and is classified under the related band-like calcification category. In the vast majority of cases — with the notable exceptions of IFIH1-related disease and rare TREX1 or ADAR1 variants — inheritance follows an autosomal recessive pattern, meaning each parent carries one copy and every subsequent conception carries a one-in-four chance of producing an affected child. A survey of 374 diagnosed patients found that RNASEH2B harbors the most frequent pathogenic mutations. Importantly, the same mutation can produce wildly different outcomes within a single family, a phenomenon termed incomplete penetrance. TREX1 mutations tend to drive the most severe, in-utero-onset course with high early mortality, whereas RNASEH2B variants are associated with somewhat milder neurological impairment, lower interferon activity, and a longer expected lifespan.
The Interferon Pathway and Neurodegeneration
At the molecular heart of AGS lies a dysregulated immune response centered on the type I interferon system — a defense mechanism first characterized more than half a century ago as a soluble factor that blocked viral replication after cells were exposed to inactivated virus. While rapid interferon induction is essential for clearing genuine infections, the AGS-related proteins reveal what happens when the system is triggered by the body's own nucleic acids rather than foreign pathogens. Research into TREX1, the RNase H2 complex, SAMHD1, and ADAR1 points to a common thread: an inappropriate buildup of self-derived nucleic acids that inappropriately activates type I interferon signaling. Mutations in IFIH1, which encodes the cytosolic double-stranded RNA sensor MDA5, further implicate aberrant nucleic-acid sensing as a driver of immune upregulation. In the mouse model, loss of RNASEH2 activity — a complex normally tasked with excising misincorporated ribonucleotides from DNA during genome surveillance — produces neuroinflammation, cerebellar atrophy, and white matter defects that closely mirror the human disease. The emerging consensus is that signaling from unrepaired DNA damage constitutes the fundamental trigger behind the progressive neurodegeneration that defines AGS.
Recognition, Misdiagnosis, and Global Prevalence
Despite its clinical distinctiveness, AGS has a relatively short formal history. Eight cases were first described in 1984, but the condition did not receive its eponymous label — Aicardi–Goutières syndrome — until 1992, and the first dedicated international conference was not convened until 2001 in Pavia, Italy. The delay in recognition is understandable: the neurological and hematological features of AGS closely mimic congenital viral infections acquired in utero, and certain characteristics overlap with systemic lupus erythematosus, an autoimmune condition. This diagnostic mimicry, combined with the absence of a single unifying genetic cause, has contributed to what researchers describe as near-certain under-diagnosis across all populations worldwide. By 2014, at least 400 cases had been documented globally, a figure almost certainly representing a fraction of true prevalence. The condition affects all ethnic and geographic groups, yet its rarity and its resemblance to more common disorders mean that many affected children likely remain unidentified. It is also critical to note that AGS is entirely distinct from Aicardi syndrome, another rare neurological condition, and the shared surname has occasionally caused confusion in both clinical and public discourse.
Frequently Asked Questions
What is Aicardi syndrome?
Aicardi syndrome is a rare genetic disorder that disrupts normal brain development, impairs vision, and causes epilepsy. Its core features include a missing or underdeveloped corpus callosum, white retinal spots known as lacunae, and seizures that typically begin in infancy as spasms.
Who is Aicardi syndrome named after?
The condition honors French neurologist Jean Dennis Aicardi, who in 1965 published the first formal description based on nine affected girls. His work established the diagnostic triad that still defines the syndrome today.
What are Aicardi syndrome's hallmark signs?
The classic triad consists of agenesis or hypoplasia of the corpus callosum, retinal lacunae, and epileptic seizures—most often presenting as infantile spasms. Moderate to severe intellectual disability commonly accompanies these neurological and ocular findings.
Who does Aicardi syndrome affect?
The syndrome has been identified almost exclusively in girls, with the only known male cases occurring in individuals who also carry Klinefelter syndrome and thus an extra X chromosome. This pattern strongly suggests the causative gene resides on the X chromosome.
Why is Aicardi syndrome important in child neurology?
It stands as a landmark example of an X-linked condition that profoundly alters brain structure, vision, and seizure activity, making it a staple topic in pediatric neurology curricula. First described in 1965, it continues to inform research into how chromosomal dosage shapes neurological development.
More in Rare syndromes 1-24
Spotted an error? Know more?
Reader corrections go straight into our review queue. Suggest an edit · How this site is sourced